
In our professional lives, we may get only one opportunity to truly advance the field in a meaningful way. Fully realizing an opportunity like that requires a focused, dedicated team working collaboratively toward a shared goal.
✓Enterprise Head & Neck Disease Group Chair @MayoCancerCare. Head & Neck Division Chair @MayoRadOnc.

In our professional lives, we may get only one opportunity to truly advance the field in a meaningful way. Fully realizing an opportunity like that requires a focused, dedicated team working collaboratively toward a shared goal.

🗣️☢️Intriguing abstract #ESMO25 - possible increased systemic response after hypofractionated RT (36Gy/12fx) with pembro for R/M-HNSCC? Looking forward to more details!

Congratulations to @KenOlivierMD , the latest FASTRO from @MayoRadOnc! #ASTRO2025

Great work by @MayoRadOnc emphasizing our specialty’s need to engage with the cultural perception of radiation. Congrats to Drs. Elsa Sutton, Scott Lester, and the study team for this unique perspective. #ASTRO2025


Congrats to @DavidRoutmanMD @KatieVanAbelMD @LindaXYinMD and our stellar MS4 Cecelia Hidalgo for presenting our real world data with DART (30-36 Gy) for HPVOPC. 282 patients and 97% PFS for int risk group. DART is a standard tx for int risk pts @MayoCancerCare #ASTRO25

This is a population that continues to grow with the ongoing HPV epidemic, one that doesn't look to end soon. We owe it to them to continue exploring better options. Grateful as always to @MayoRadOnc @MayoCancerCare @MayoClinicENT and esp our pts for supporting this work.

5. Finally, more research in biological selection is needed. Whether it's functional imaging ala @imrtlee, ctDNA ala @DavidRoutmanMD, AI-assisted involved node selection ala @DavidSherMD, or chromosome instability ala @pipcosper (and many more strategies!), we need better data.

4b. In this context, DART provides an alternative between "watchful waiting" and "nuke it from orbit, it's the only way to be sure." Absolute radiation dose is important. 30 Gy demonstrated persistent QOL benefits at 2 yrs, something 50 Gy did not.

4a. Regardless of how you feel about TORS, you will see adjuvant patients in your referrals. Having adjuvant options is important. Particularly in the eternal tumor board discussion on what to do pts with only 1-2 int risk factors after surgery.

3. Several commentators stated that they would prefer no TORS altogether. Seeing the outcomes in our pts, I can unequivocally say that had I earlier stage HPVOPSCC, I would want TORS followed by DART for myself rather than 70 or even 60 Gy of CRT.

2. ENE- patients. Given the excellent PFS, now in both 1273 and 1675, and the large difference in acute toxicity, late toxicity, and QOL, we do offer DART off trial to patients with int risk disease. DART 2.0's focus will be selecting which of these patients can be observed.

So what are our final thoughts: 1. ENE+ patients. Adjuvant de-escalation without biologic selection is not ready for prime time. @DavidRoutmanMD and DART 2.0 will hopefully answer some of these questions with ctDNA.

Absolute numbers for recurrence were small, so perhaps we were unlucky. But it's challenging for me to reconcile a difference in primarily distant control based upon differences in locoregional RT dose. I would stress our thoughts on cis vs doce are hypothesis generating.

The juicy bit is of course the ENE+ cohort, particularly the AJCC 8 pN2. I dont' know if cis meaningfully improves distant control for the ENE+ and pN2 pts. Like Dr. Sher says, this goes against much of the established HN literature.

We were very happy to find a SS difference in grade 3 toxicity, and also like David points out a large difference in grade 2 toxicity. This is reflected in SS differences in patient QOLs even at 2 years. Take home: grade 2s really do matter.